Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabet...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Online Access: | http://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-a4451 |
| _version_ | 1797936110827995136 |
|---|---|
| author | Jason Seewoodhary Leanne Griffin Stephen C Bain |
| author_facet | Jason Seewoodhary Leanne Griffin Stephen C Bain |
| author_sort | Jason Seewoodhary |
| collection | DOAJ |
| description | Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight loss |
| first_indexed | 2024-04-10T18:24:40Z |
| format | Article |
| id | doaj.art-859b87f723894cad807b0051bd2e8a75 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:24:40Z |
| publishDate | 2010-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-859b87f723894cad807b0051bd2e8a752023-02-02T06:08:39ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072010-05-012010default165172Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitusJason SeewoodharyLeanne GriffinStephen C BainJason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight losshttp://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-a4451 |
| spellingShingle | Jason Seewoodhary Leanne Griffin Stephen C Bain Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus Diabetes, Metabolic Syndrome and Obesity |
| title | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_full | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_fullStr | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_full_unstemmed | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_short | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_sort | critical appraisal of once weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| url | http://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-a4451 |
| work_keys_str_mv | AT jasonseewoodhary criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT leannegriffin criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT stephencbain criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus |